BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical development across multiple solid tumors.
Data from Summit Therapeutics Inc. (NASDAQ:SMMT) and their partner Akeso for ivonescimab (PD-1xVEGF bispecific) has shown the potential to challenge standard-of-care regimens across a range of solid tumors.
The analyst notes that the data for ivonescimab have sparked interest in BioNTech’s bispecific drug, BNT327, and its potential to follow a similar path and gain value.
Also Read: BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
The analyst adds that the data for BNT327, including the latest findings presented at the European Society for Medical Oncology, show a promising clinical profile.
While direct comparisons …
Full story available on Benzinga.com